Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

The American journal of gastroenterology·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.

Journal of clinical medicine·2026
Same author

Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan.

Journal of gastroenterology·2026
Same author

Primary Hepatic Squamous Cell Carcinoma.

Diagnostics (Basel, Switzerland)·2026
Same author

Network-based insights into miRNA regulation of β-cell insulin secretion in type 2 diabetes.

iScience·2025

Related Experiment Video

Updated: Mar 8, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.

Akira Asai1, Kazuyuki Takakuma2,3

  • 1Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan. aasai@u-shizuoka-ken.ac.jp.

Methods in Molecular Biology (Clifton, N.J.)
|January 17, 2017
PubMed
Summary
This summary is machine-generated.

Researchers developed a new assay to find drugs that block Signal Transducer and Activator of Transcription (STAT) 3 and 5b protein interactions, a key step in many cancers. This method aids in discovering novel cancer therapeutics targeting STAT activation.

Keywords:
Alpha assayHigh-throughput screening (HTS)Multiplexed assaySTAT3STAT5bSrc homology 2 (SH2)

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K
Identifying Protein-protein Interaction Sites Using Peptide Arrays
07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.7K

Related Experiment Videos

Last Updated: Mar 8, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K
Identifying Protein-protein Interaction Sites Using Peptide Arrays
07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Constitutive activation of Signal Transducer and Activator of Transcription (STAT) 3 and STAT5b is common in human cancers.
  • STAT3/5b activation relies on dimerization through intermolecular pTyr-SH2 binding.
  • Inhibiting this interaction presents a viable strategy for cancer therapy.

Purpose of the Study:

  • To describe a novel multiplexed assay for assessing STAT3- and STAT5b-SH2 binding.
  • To demonstrate the application of this assay for identifying STAT3 and STAT5b antagonists.

Main Methods:

  • Development of a multiplexed assay combining AlphaLISA and AlphaScreen bead technologies.
  • The assay enables simultaneous assessment of STAT3-SH2 and STAT5b-SH2 binding in a single well.

Main Results:

  • The described assay successfully measures STAT3- and STAT5b-SH2 interactions.
  • The method is applicable for high-throughput screening to identify potential therapeutic agents.

Conclusions:

  • A novel, efficient multiplexed assay has been established for STAT3 and STAT5b antagonist discovery.
  • This assay provides a valuable tool for developing targeted cancer therapies by inhibiting STAT protein activation.